Salix Pharmaceuticals announced its affiliate has entered into a license agreement with the University of California via UCLA’s Technology Development Group for certain intellectual property relating to an investigational compound targeting the pituitary adenylate cyclase receptor 1 in non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and various other gastrointestinal and liver diseases.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.